Nektar Therapeutics
NASDAQ:NKTR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.42
1.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Nektar Therapeutics
Nektar Therapeutics
Capital Expenditures
Nektar Therapeutics
Capital Expenditures Peer Comparison
JNJ
BMY
PFE
MRK
LLY
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Capital Expenditures
-$608k
|
CAGR 3-Years
61%
|
CAGR 5-Years
53%
|
CAGR 10-Years
23%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Capital Expenditures
-$4.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
Pfizer Inc
NYSE:PFE
|
Capital Expenditures
-$3.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Capital Expenditures
-$3.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Capital Expenditures
-$8.3B
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-18%
|
See Also
What is Nektar Therapeutics's Capital Expenditures?
Capital Expenditures
-608k
USD
Based on the financial report for Jun 30, 2024, Nektar Therapeutics's Capital Expenditures amounts to -608k USD.
What is Nektar Therapeutics's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
23%
Over the last year, the Capital Expenditures growth was 53%. The average annual Capital Expenditures growth rates for Nektar Therapeutics have been 61% over the past three years , 53% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet
